A phase 2 study presented at the Conference on Retrovirus and Opportunistic Infections (CROI) in Denver showed that a once-daily oral combination therapy for HIV consisting of bictegravir plus lenacapavir is more effective than complex regimens. The study involved 128 participants who had been on a stable baseline regimen for six months before screening, with both the low-dose and high-dose combination regimens showing good virologic suppression at 6 months. The study found favorable safety profiles with mild side effects, and the phase 3 trial is expected to conclude by the end of 2025, aiming to simplify HIV treatment and increase adherence. Long-term safety data and unanswered questions about antiretroviral resistance mutations and drug interactions remain to be explored.
Source link
New Once-Daily HIV Oral Alternative Advances
